Improved treatment results for childhood acute myeloid leukemia in Taiwan

D. C. Liang, T. T. Chang, K. H. Lin, D. T. Lin, M. Y. Lu, S. H. Chen, H. C. Liu, M. T. Lin, M. T. Lee, S. G. Shu, T. K. Chang, J. S. Chen, C. C. Hsiao, I. J. Hung, Y. L. Hsieh, R. L. Chen, S. N. Cheng, W. H. Chang, C. H. Lee, K. S. Lin

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used. From January 1, 1997, to December 31, 2002, 141 children younger than 17 years old with de novo AML were enrolled. In total, 117 patients with non-APL AML were treated with induction therapy of idarubicin and cytarabine (Ara-C), postremission therapy with high-dose Ara-C - containing regimens for four monthly courses, and moderate-dose therapy with idarubicin and Ara-C for four monthly courses. The first 19 patients with APL were treated with all-trans retinoic acid, idarubicin and Ara-C, with the remaining five patients receiving all-trans retinoic acid and idarubicin, followed by maintenance therapy for 2 years. Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone. The remission rate in the AML-97A study was 90%, the 5-year survival 51±5.3% (s.e.) and the 5-year event-free survival 50±4.8%; for APL, these were 100%, 86±7.0, and 75±9.8%. For the whole group, the 5-year survival was 57±4.7% and the 5-year event-free survival 54±4.4%. The AML-97A regimen was well tolerated.

Original languageEnglish
Pages (from-to)136-141
Number of pages6
JournalLeukemia
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Fingerprint

Taiwan
Acute Myeloid Leukemia
Idarubicin
Cytarabine
Acute Promyelocytic Leukemia
Tretinoin
Therapeutics
Disease-Free Survival
Survival
Stem Cell Transplantation
Pediatrics
Drug Therapy

Keywords

  • Childhood acute myeloid leukemia
  • Outcome
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Liang, D. C., Chang, T. T., Lin, K. H., Lin, D. T., Lu, M. Y., Chen, S. H., ... Lin, K. S. (2006). Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia, 20(1), 136-141. https://doi.org/10.1038/sj.leu.2403979

Improved treatment results for childhood acute myeloid leukemia in Taiwan. / Liang, D. C.; Chang, T. T.; Lin, K. H.; Lin, D. T.; Lu, M. Y.; Chen, S. H.; Liu, H. C.; Lin, M. T.; Lee, M. T.; Shu, S. G.; Chang, T. K.; Chen, J. S.; Hsiao, C. C.; Hung, I. J.; Hsieh, Y. L.; Chen, R. L.; Cheng, S. N.; Chang, W. H.; Lee, C. H.; Lin, K. S.

In: Leukemia, Vol. 20, No. 1, 01.2006, p. 136-141.

Research output: Contribution to journalArticle

Liang, DC, Chang, TT, Lin, KH, Lin, DT, Lu, MY, Chen, SH, Liu, HC, Lin, MT, Lee, MT, Shu, SG, Chang, TK, Chen, JS, Hsiao, CC, Hung, IJ, Hsieh, YL, Chen, RL, Cheng, SN, Chang, WH, Lee, CH & Lin, KS 2006, 'Improved treatment results for childhood acute myeloid leukemia in Taiwan', Leukemia, vol. 20, no. 1, pp. 136-141. https://doi.org/10.1038/sj.leu.2403979
Liang, D. C. ; Chang, T. T. ; Lin, K. H. ; Lin, D. T. ; Lu, M. Y. ; Chen, S. H. ; Liu, H. C. ; Lin, M. T. ; Lee, M. T. ; Shu, S. G. ; Chang, T. K. ; Chen, J. S. ; Hsiao, C. C. ; Hung, I. J. ; Hsieh, Y. L. ; Chen, R. L. ; Cheng, S. N. ; Chang, W. H. ; Lee, C. H. ; Lin, K. S. / Improved treatment results for childhood acute myeloid leukemia in Taiwan. In: Leukemia. 2006 ; Vol. 20, No. 1. pp. 136-141.
@article{3f81c6a3a9494ad7aa7ae503a4256776,
title = "Improved treatment results for childhood acute myeloid leukemia in Taiwan",
abstract = "To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used. From January 1, 1997, to December 31, 2002, 141 children younger than 17 years old with de novo AML were enrolled. In total, 117 patients with non-APL AML were treated with induction therapy of idarubicin and cytarabine (Ara-C), postremission therapy with high-dose Ara-C - containing regimens for four monthly courses, and moderate-dose therapy with idarubicin and Ara-C for four monthly courses. The first 19 patients with APL were treated with all-trans retinoic acid, idarubicin and Ara-C, with the remaining five patients receiving all-trans retinoic acid and idarubicin, followed by maintenance therapy for 2 years. Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone. The remission rate in the AML-97A study was 90{\%}, the 5-year survival 51±5.3{\%} (s.e.) and the 5-year event-free survival 50±4.8{\%}; for APL, these were 100{\%}, 86±7.0, and 75±9.8{\%}. For the whole group, the 5-year survival was 57±4.7{\%} and the 5-year event-free survival 54±4.4{\%}. The AML-97A regimen was well tolerated.",
keywords = "Childhood acute myeloid leukemia, Outcome, Treatment",
author = "Liang, {D. C.} and Chang, {T. T.} and Lin, {K. H.} and Lin, {D. T.} and Lu, {M. Y.} and Chen, {S. H.} and Liu, {H. C.} and Lin, {M. T.} and Lee, {M. T.} and Shu, {S. G.} and Chang, {T. K.} and Chen, {J. S.} and Hsiao, {C. C.} and Hung, {I. J.} and Hsieh, {Y. L.} and Chen, {R. L.} and Cheng, {S. N.} and Chang, {W. H.} and Lee, {C. H.} and Lin, {K. S.}",
year = "2006",
month = "1",
doi = "10.1038/sj.leu.2403979",
language = "English",
volume = "20",
pages = "136--141",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Improved treatment results for childhood acute myeloid leukemia in Taiwan

AU - Liang, D. C.

AU - Chang, T. T.

AU - Lin, K. H.

AU - Lin, D. T.

AU - Lu, M. Y.

AU - Chen, S. H.

AU - Liu, H. C.

AU - Lin, M. T.

AU - Lee, M. T.

AU - Shu, S. G.

AU - Chang, T. K.

AU - Chen, J. S.

AU - Hsiao, C. C.

AU - Hung, I. J.

AU - Hsieh, Y. L.

AU - Chen, R. L.

AU - Cheng, S. N.

AU - Chang, W. H.

AU - Lee, C. H.

AU - Lin, K. S.

PY - 2006/1

Y1 - 2006/1

N2 - To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used. From January 1, 1997, to December 31, 2002, 141 children younger than 17 years old with de novo AML were enrolled. In total, 117 patients with non-APL AML were treated with induction therapy of idarubicin and cytarabine (Ara-C), postremission therapy with high-dose Ara-C - containing regimens for four monthly courses, and moderate-dose therapy with idarubicin and Ara-C for four monthly courses. The first 19 patients with APL were treated with all-trans retinoic acid, idarubicin and Ara-C, with the remaining five patients receiving all-trans retinoic acid and idarubicin, followed by maintenance therapy for 2 years. Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone. The remission rate in the AML-97A study was 90%, the 5-year survival 51±5.3% (s.e.) and the 5-year event-free survival 50±4.8%; for APL, these were 100%, 86±7.0, and 75±9.8%. For the whole group, the 5-year survival was 57±4.7% and the 5-year event-free survival 54±4.4%. The AML-97A regimen was well tolerated.

AB - To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used. From January 1, 1997, to December 31, 2002, 141 children younger than 17 years old with de novo AML were enrolled. In total, 117 patients with non-APL AML were treated with induction therapy of idarubicin and cytarabine (Ara-C), postremission therapy with high-dose Ara-C - containing regimens for four monthly courses, and moderate-dose therapy with idarubicin and Ara-C for four monthly courses. The first 19 patients with APL were treated with all-trans retinoic acid, idarubicin and Ara-C, with the remaining five patients receiving all-trans retinoic acid and idarubicin, followed by maintenance therapy for 2 years. Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone. The remission rate in the AML-97A study was 90%, the 5-year survival 51±5.3% (s.e.) and the 5-year event-free survival 50±4.8%; for APL, these were 100%, 86±7.0, and 75±9.8%. For the whole group, the 5-year survival was 57±4.7% and the 5-year event-free survival 54±4.4%. The AML-97A regimen was well tolerated.

KW - Childhood acute myeloid leukemia

KW - Outcome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33644988994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644988994&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403979

DO - 10.1038/sj.leu.2403979

M3 - Article

C2 - 16281075

AN - SCOPUS:33644988994

VL - 20

SP - 136

EP - 141

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -